Cargando…

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France

SUMMARY: The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France. INTRODUCTION:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiligsmann, M., Reginster, J.-Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423313/ https://www.ncbi.nlm.nih.gov/pubmed/30701342 http://dx.doi.org/10.1007/s00198-018-04821-7

Ejemplares similares

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
por: Casado, Enrique, et al.
Publicado: (2023)

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
por: Hiligsmann, M., et al.
Publicado: (2021)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis
por: Hiligsmann, M., et al.
Publicado: (2013)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007)

Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women
por: Chandran, M., et al.
Publicado: (2020)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
por: Kinov, Plamen, et al.
Publicado: (2012)

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
por: McClung, Michael R., et al.
Publicado: (2012)

An open‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate
por: Kleinermans, Diane, et al.
Publicado: (2022)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2018)

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
por: McClung, M. R., et al.
Publicado: (2012)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)

Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis
por: Thomasius, Friederike, et al.
Publicado: (2021)

Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2020)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2012)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
por: Tanaka, Mizue, et al.
Publicado: (2014)

Use of risedronate for consolidation and callus formation in Colles fractures in postmenopausal women: SOLID study
por: Oliveira, Lindomar Guimarães, et al.
Publicado: (2015)

The development of a personalized patient education tool for decision making for postmenopausal women with osteoporosis
por: Hiligsmann, M., et al.
Publicado: (2016)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
por: Meunier, P. J., et al.
Publicado: (2009)

Effects of Yogasanas on osteoporosis in postmenopausal women
por: Motorwala, Zainab S, et al.
Publicado: (2016)

Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
por: Yang, Chengzhi, et al.
Publicado: (2020)

Anabolic treatments for osteoporosis in postmenopausal women
por: Hassan, Neelam, et al.
Publicado: (2021)

Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
por: Kang, Jung-Yoon, et al.
Publicado: (2022)

Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
por: Rizzoli, René, et al.
Publicado: (2011)

Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
por: Chen, Mingsheng, et al.
Publicado: (2016)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
por: Söreskog, E., et al.
Publicado: (2021)

Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
por: Li, Nannan, et al.
Publicado: (2023)

Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report
por: Evangelatos, Gerasimos, et al.
Publicado: (2021)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n98augocj416eknpfbrehccbli